Peder Mohr Olsen

Title: Peder Mohr Olsen: Innovator in Controlled Release Pharmaceutical Compositions

Introduction

Peder Mohr Olsen is a notable inventor based in Kirke Hyllinge, Denmark. He has made significant contributions to the field of pharmaceuticals, particularly in the development of controlled release compositions for oral use.

Latest Patents

Olsen holds two patents that focus on controlled release pharmaceutical compositions containing midodrine and its active metabolite, desglymidodrine. His first patent describes a novel composition designed to release these compounds after oral intake, allowing for a fast peak plasma concentration followed by a prolonged and stable plasma concentration. This innovative approach aims to maintain a therapeutically effective concentration of desglymidodrine for at least 10-16 hours, minimizing side effects such as supine hypertension. The second patent introduces a pharmaceutical kit that includes these controlled release compositions, further enhancing the treatment options for conditions like orthostatic hypotension and urinary incontinence.

Career Highlights

Olsen is associated with Nycomed Austria GmbH, where he has been instrumental in advancing pharmaceutical technologies. His work has focused on improving patient outcomes through innovative drug delivery systems.

Collaborations

Olsen has collaborated with notable colleagues, including Poul Egon Bertelsen and Annette Skinhøj, contributing to the development of effective pharmaceutical solutions.

Conclusion

Peder Mohr Olsen's work in controlled release pharmaceutical compositions represents a significant advancement in the treatment of various medical conditions. His innovative patents and collaborations highlight his commitment to improving healthcare through scientific research and development.